Biosimilars are being widely adopted by rheumatologists in Australia, according to figures on etanercept use sourced from the OPAL dataset. Findings presented at the ARA 2021 meeting by Professor Peter Youssef of Sydney University showed that in 2020, 46% of patients with rheumatoid arthritis commencing etanercept in any line of therapy were prescribed the biosimilar. ...
Biosimilars embraced by rheumatologists in Australia, etanercept usage data suggest
11 Jun 2021